HC Wainwright Raises AnaptysBio (NASDAQ:ANAB) Price Target to $66

Biotechnology company AnaptysBio sees price target increase from $51 to $66 by HC Wainwright analysts.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

HC Wainwright, an equity research firm, has increased its price target for AnaptysBio (NASDAQ:ANAB) from $51.00 to $66.00 and maintained a "buy" rating on the biotechnology company's stock. The new price target represents a potential upside of 24.93% from the company's previous closing price.

Why it matters

The price target increase by HC Wainwright suggests that the analysts see significant growth potential for AnaptysBio, a clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation. This positive outlook could signal increased investor interest and confidence in the company's pipeline and future prospects.

The details

In their research report, HC Wainwright cited AnaptysBio's progress in its clinical-stage programs addressing dermatological and inflammatory disorders as the primary reasons for the price target increase. The company's proprietary somatic hypermutation platform has enabled it to rapidly generate and refine human antibodies with optimized efficacy and safety profiles.

  • The price target increase was announced on Wednesday, March 4, 2026.

The players

HC Wainwright

An equity research firm that covers AnaptysBio and has increased its price target on the company's stock.

AnaptysBio

A clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation, using its proprietary somatic hypermutation platform.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The price target increase by HC Wainwright reflects the analysts' confidence in AnaptysBio's ability to continue advancing its pipeline of therapeutic antibody candidates, which could lead to potential growth and value creation for the company and its investors.